Pharmaceutical innovation in healthcare is a multifaceted process involving numerous private and public stakeholders. New blockbuster drugs, curative therapies, and additional uses for existing medications all represent innovation and are often cited as reasons to seek care and treatment in the United States. But this doesn’t come without a price. The healthcare sector continues to see high prices and soaring costs on top of rising disease burden and inequitable outcomes across populations.
This gathering will examine the trade-offs inherent in focusing on certain areas of innovation while sidelining others. Key topics include determining who sets prices, who really receives the benefit of pharmaceutical innovation, and ultimately, for whom we are innovating. Our goal is to initiate a meaningful dialogue that re-examines our highest aspirations and opportunities in US healthcare.
